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Abstract 
Background: The aim was to determine the level of inflammatory cytokines, eosinophil cationic protein and IgE in 
allergic rhinitis (AR) patients.
Subjects and methods: Blood samples were taken from 88 AR patients and 88 healthy controls (HC). Each sample 
was analysed for eosinophil counts by flow cytometry, IgE by ECLIA, ECP, IL-17, and IL-33 by using ELISA test.
Results: There was no significant difference between AR patients and the control group in age and gender. Levels 
of eosinophils, IgE, ECP, IL-17, IL-33 and the total symptom scores were significantly higher in AR patients than the HC 
(P = 0.0001). Serum ECP correlated with IL-17 (P = 0.041, r = 0.42), IL-33 (P = 0.0001, r = 080), and IgE levels (P = 0.017, 
r = 0.45) in the R patients. There was no correlation between IL-17 and IL-33. There was a correlation between symp-
tom scores and eosinophils (P = 0.026, r = 0.52), and IgE (P = 0.001, r = 0.60) in the patients. No correlation was 
observed between symptom scores and ECP, IL-17, and IL-33 in the AR patient.
Conclusions: Patients with AR have significant higher serum levels of ECP, IL-17, and IL-33 than healthy controls. This 
indicates that these markers could be used to in order to diagnose AR and to monitor disease. Inhibitory molecules to 
IL-17 and IL-33 may be considered as novel treatment strategies.
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Highlights
• There was relationship between serum ECP and 
IL-17, IL-33, IgE, and AR disease, respectively.
• A relationship was established between symptoms, 
blood eosinophil level and serum IgE level.
• IL-17 secreted by Th17 cell, acts upon various 
immune cells and might have a role in AR.
• IL-17 and IL-33, ECP may be considered as novel 
therapeutic targets in AR.
Background
Allergic rhinitis (AR) is a disorder with increasing preva-
lence, already affecting 10–40% of the worldwide popula-
tion [1, 2]. The symptoms can be non-specific and might 
be ignored by patients and physicians. Many individuals 
with disease do not report their complaints or seek treat-
ment [3]. Accordingly, AR is considered a social problem 
that negatively affects patients’ quality of life and perfor-
mance [4]. Recently, on the basis of frequency and dura-
tion of symptoms, AR has been categorized as either 
intermittent or persistent [5].
Characteristic for the onset of AR is an allergen specific 
IgE mediated activation of mast cells (MCs) in the nasal 
mucosa leading to mediator release and acute inflamma-
tion. This is followed, several hours after the initial aller-
gen exposure by release of other inflammatory mediators, 
accumulation of inflammatory cells and a recurrence of 
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symptoms. Low-grade underlying inflammation often 
remains in the mucosa [6].
Apart from MCs, other inflammatory immune cells 
and their mediators contribute to the inflammation in 
AR. Released mediators are associated with and attract a 
T-helper cell type 2 (Th2) cells and eosinophils that con-
tribute to pathology [7]. MCs and eosinophils are consid-
ered to be central effector cells in the allergic reaction [8, 
9]. Eosinophil cationic protein (ECP) is one of the media-
tors that upon activation is released from eosinophils 
during allergic diseases [10]. ECP possesses cytotoxic 
ribonuclease activity and have bactericidal and antivi-
ral properties [11, 12]. The mechanism for killing target 
cells is by the formation of transmembrane pores and 
channels [10]. ECP has been quantified in bodily fluids, 
including serum, bronchoalveolar lavage (BAL) and nasal 
secretions of patients with allergic and other inflamma-
tory diseases [13].
Interleukin-17 (IL-17) is a cytokine produced by Th17 
(Th17) cells which is involved in host defences, the induc-
tion of inflammation and autoimmunity [14, 15]. Studies 
have indicated involvement of IL-17 in allergic responses 
[16]. However, the contribution of Th17 inflammation in 
AR has not been thoroughly assessed [17, 18].
Interleukin-33 (IL-33), is a member o the IL-1 family 
that is involved in the Th2 mediated immune response, 
host defences and allergic diseases [19]. The cytokine 
is produced by a variety of different cells such as mac-
rophages, dendritic cells (DCs), MCs, fibroblasts, smooth 
muscle cells, endothelial- and epithelial cells [20].
Serum specific IgE (sIgE) antibody test and the skin 
prick test (SPT) are used to detecting AR [21]. IgE has 
been found to be highly specific, while SPT on the other 
hand is more sensitive [22]. The aim of this study was to 
analyze the level of the cytokines IL-17, IL-33, the eosin-
ophil product ECP, in relation to IgE, in AR patients. We 
wanted to determine the usefulness of markers other 
than IgE and whether informative correlations between 
the inflammatory cells, their mediators and allergic 
symptoms existed. Such findings would indicate the 
mediators’ specific involvement and possible reciprocal 
relationship in AR disease.
Subjects and methods
Patients and setting of the study
For this study, 88 patients with AR and 88 healthy con-
trols (HC) were recruited and compared. Samples from 
the subjects were collected at the laboratory of Public 
Health and Ali Kamal Health Center, Sulimani, Iraq. The 
complete blood count (CBC) and IgE level analysis were 
performed in the Public Health laboratory in Sulaimani 
(Table 1).
Inclusion and exclusion criteria
All of the AR patients were assessed by a consultant ear-, 
nose- and throat-specialist (ENT) according to the Brit-
ish Society for Allergy and Clinical Immunology (BSACI) 
criteria. AR was diagnosed based on history, symptoms, 
clinical examination and by the measurement of total 
serum IgE and CBC. The healthy control subjects were 
selected as having no history of allergy of any other 
chronic diseases. Patients, who had undergone treatment 
for allergies, before the blood was drawn, were excluded 
from this study.
Ethical considerations
Ethical approval for the study was provided by The Ethic 
Committee of the college of Medicine, University of 
Sulaimani. Informed consent for the study was obtained 
from each patient and healthy individual that agreed to 
participate in the study.
Specimens
Eight milliliter of venous blood were drawn from each 
participant in the study. Three milliliter were stored in an 
ethylene diamine tetra-acetic acid (EDTA) tubes used for 
an eosinophil test. The remaining 5 mL were transferred 
to a clot activator tube and centrifuged at 4500 RPM for 
10  min. One aliquot of the serum was used for the IgE 
measurement and another was stored at − 80  °C until 
further use.
Preparation and procedure of the different kit
Optical Flow Cytometry Kit for Detection of Eosinophils 
in Human Blood was used according to the manufactur-
er’s instructions (Orphee, France). IgE measurement in 
serum was performed using ECLIA kit according to the 
manufacturer’s instructions (Roch, USA). IL-17 and IL-33 
was measured in serum using ELISA kits according to the 
Table 1 Characteristics of  both  patients and  healthy 
control—according to  age, sex, symptoms, serum IgE 
and eosinophil
P-value <0.05 (significant)
ns Non-significant
Allergic 
rhinitis 
(n = 88)
Healthy 
subjects 
(n = 88)
P value
Age (year), (M ± SD) 33.2 ± 11.9 34 ± 11.6 0.363
Sex (female/male) 66/22 62 / 26 0.36 (ns)
Serum total IgE (IU/mL), (M+SD) 161 ± 221 35 ± 26 0.0001
Eosinophil  (109/L) (M+SD) 0.35 ± 2.9 0.23 ± 1.05 0.0004
Symptom 1.80 ± 0.40 0.01 0.0001
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manufacturer’s instructions (Abcam, UK). Human ECP 
(Eosinophil Cationic Protein) was measured in serum in 
accordance with directives provided by the manufacturer 
(Diagnostics Development, Uppsala, Sweden).
Statistical analysis
Statistical analyses were performed using GraphPad ver-
sion 5. Results are expressed as mean ± standard error 
(mean ± SE) or mean ± standard deviation (mean ± SD) 
as indicated. Data was analysed using the Student’s t-test 
or the Mann–Whitney-U test for comparison of two 
groups, or one-way analysis of variance for multiple com-
parisons (ANOVA). The Pearson product-moment corre-
lation coefficient (r) was used to assess the relationship 
between cytokines, eosinophil and IgE levels. A P-value 
equal to or less than 0.05 was considered statistically sig-
nificant (S). Otherwise, results from statistical analysis 
were considered non-significant (NS).
Results
Characteristics of patients and healthy control
This study included 88 patients with AR and as a con-
trol population, 88 apparently healthy subjects. Table  1 
illustrates the basic characteristics of patients and 
the healthy controls. There were no difference in age 
comparing patients (33.2 ± 11.9  years of age) and HC 
(34.0 ± 11.6  years of age) and the male female ratio was 
in a similar range (female/male ration, patients: 66/22, 
healthy controls: 62/26). Patients had significantly 
higher level of IgE measurable in the serum than the 
healthy controls (161.0  IU/mL compared to 34.9  IU/
mL, P = 0.0001). The clinical assessment showed high 
symptom score in the patients (1.80 ± 0.4, HC: 0.01, 
P = 0.0001). Of the patients, 80% had perennial and the 
remainder seasonal AR.
Comparison
All AR patients’ had blood eosinophil count above the 
normal range. The patients’ blood eosinophil count was 
significantly higher that the HCs’ (see Table 1, 3.5 × 109 
compared to 2.3 × 109, and Fig. 1a, P = 0.0004).
IgE was detectable in all patients serum and was con-
sidered elevated if above 100  IU/mL. While all the HC 
subjects had IgE levels within the normal range many of 
the patients had elevated levels (P = 0.0001, Fig. 1b).
AR patients and healthy controls had detectable levels 
of ECP in their serum. Statistical analysis showed serum 
ECP levels in the AR patients serum were significantly 
higher than that of the HCs’ (3.80 ± 6.83  μg/mL and 
1.70 ± 2.53 μg/mL respectively, P = 0.0001, Fig. 2a).
The cytokine IL-17 was detectable in 46 of the 88 
AR patients but low or undetectable in HCs. A signifi-
cant difference in the IL-17 serum levels was therefore 
found when comparing AR patients and healthy con-
trols (169 ± 240  pg/mL and 27.0 ± 30.2 respectively, 
P = 0.0001, Fig. 2b).
Level of IL-33 was detectable in 67 of the 88 AR 
patients. Figure 2c shows the serum levels of IL-33 which 
is significantly higher in the AR group (1.18 ± 1.17  pg/
mL) than the HC group (0.64 ± 1.10 pg/mL, P = 0.0001).
Correlation
To assess whether there was a relationship between 
inflammatory mediators and cytokines present in 
serum of the 88 AR patients, correlation studies were 
performed. Figure  3a shows that a positive correla-
tion emerged when comparing ECP and IL-17 levels 
(P = 0.041, R = 0.42). Furthermore as is shown in Fig. 3b, 
there was a positive correlation comparing ECP and 
IL-33 (P = 0.0001, R = 0.80). Statistical analysis showed 
on the other hand no correlation between IL-17 and 
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Fig. 1 a Comparison of blood eosinophil counts  (109/L) in AR patients and HC subjects and b total IgE level (IU/mL) in serum of AR patients and 
HC. Error bars indicate median values
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IL-33 in the patients (P = 0.091, R = 0.182, Fig. 3c). Also 
level of ECP and IgE in serum of the patients was found 
to correlate (P = 0.017, R = 0.45).
Finally we wanted to determine whether there is a cor-
relation between the patients’ symptoms and any of the 
inflammatory mediators or the cytokines. Such correla-
tion was observed when comparing blood eosinophil 
levels or IgE with the patients’ symptoms (Table 2). ECP, 
IL-17 and IL-33 levels did not correlate with the patients 
symptom scores (Table 2).
Discussion
This study has shown that patients with allergic rhini-
tis experienced symptoms that relate to levels of IgE in 
serum and number of eosinophils in the blood. Further-
more by measurement of ECP and cytokines we have 
shown that the disease can be driven by eosinophils, 
IL-33 and a Th17 type inflammation. Our findings seem 
to suggest a reciprocal relationship between eosinophils 
and Th17 cells which is independent of IL-33.
The mean blood eosinophil counts in this study were 
significantly higher in AR patients than in the HC 
subjects. A similar finding was also observed by Beppu 
et  al. [23]. Eosinophils are also present in healthy indi-
viduals, but in allergic diseases the release of various 
mediators such as IL-5, IL-3, and GM-CSF promotes the 
production and activation of the cells. Eosinophils do in 
turn secrete mediators that increase the allergic inflam-
mation [24]. One of the eosinophil mediators is ECP 
which was also higher in the serum of patients with AR 
than in the healthy individuals in the present study. Simi-
lar results have been reported before [23, 25]. A review 
of data performed by Bystrom et  al. confirmed that an 
elevated ECP concentration in the serum of AR patients 
is associated with human epithelial cell damage in the 
respiratory tract inflammatory disease [13].
In our study, levels of IL-17 in serum were significantly 
higher in AR patients compared to the HC group. Simi-
lar result has been reported in several other studies [39]. 
Milovanovic et al. showed in an experimental study that 
the involvement of IL-17/Th17 cells in allergy and they 
presented evidence that IL-17 enhances IgE produc-
tion by human B cells in allergic patients suffering from 
asthma and atopic dermatitis compared with normal 
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Fig. 2 Difference in serum level of a ECP concentration (μg/L), b IL-17 (pg/mL), c IL-33 (pg/mL) comparing AR patients and HC. Error bars indicate 
median values
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controls. They found that after the removal of the Th17 
cells in  vitro from the peripheral blood mononuclear 
cells (PBMCs) of allergic patients led to a decrease in IgE 
levels Addition of recombinant IL-17 to PBMCs on the 
other hand restores the level [26]. It is not known what 
is driving Th17 cell response in AR but it could be due 
to reduced number of regulatory T cells or antigen inde-
pendent CD8+ suppressive T cells [27, 28]. High serum 
IL-17 levels may be associated with nasal inflammation, 
so targeting IL-17 (or augmentation of regulatory of 
suppressive T cells) could be a useful therapy in the treat-
ment of AR disease [29].
Serum levels of IL-33 were significantly higher in the 
AR patients than in the HC group in our study. This is 
in accordance to the results presented in previous stud-
ies [30, 31]. Ketelaar et al. showed that IL-33 is present at 
very low levels in the serum of asthma patients using the 
ELISA technique, and this is in agreement with our find-
ing; we did also detect low levels of the IL-33 in serum of 
patients with AR using the same technique [32]. A litera-
ture review by Rogala and Gluck concluded that IL-33 is 
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Fig. 3 a Correlation between levels of ECP and IL-17, b between ECP and IL-33, c between IL-17 and IL-33 and d between ECP and IgE in serum of 
patients with AR
Table 2 Correlation between symptoms and different markers in patients
ns non-significant
P-value< 0.05 (significant)
*, ** P = 0.05, 0.01 compared with patients with allergic rhinitis
Eosinophil level 
in blood
IgE level in blood ECP positive IL-17 positive IL-33 positive
Symptoms
 R-value 0.51 0.60 0.64 − 0.14 0.42
 P value 0.026 0.0054 0.277 0.098 0.35
 P value * ** ns ns ns
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a cytokine of interest but with both proinflammatory and 
anti-inflammatory properties. Hence, IL-33 is involved 
in Th2 mediated inflammatory responses in AR, but has 
protective effects in cardiovascular disease [33]. IL-33 
has shown inhibitory properties in osteoporosis, a dis-
ease suggested to be promoted by IL-17. IL-17 is known 
to directly augmenting osteoclast development while 
IL-33 in was suggested to prevent such differentiation 
in favour of IL-4 production and alternatively activated 
macrophages [34]. In AR IL-33 can augment inflamma-
tion through activation of several types of cells includ-
ing Th2 cells, MCs and eosinophils through its receptor 
ST2. We did also find a significant correlation between 
serum ECP and IL-33 levels in the AR patients. IL-33 can 
directly enhance eosinophils survival and degranulation 
[17], but no previous studies have proven a correlation 
between ECP and IL-33 in AR disease. These findings 
indicated that IL-33 and ECP play a key role in the nasal 
inflammation of AR patients and may be useful to assess 
the severity of the disease. Our finding indicates as well 
that the IL-33/ST2 pathway might serve as a therapeutic 
target to treat allergic inflammation [20].
In the current study, a significant correlation has been 
found between serum ECP and IL-17 levels in the AR 
patients. No previous studies have showed a correlation 
between ECP and IL-17 in patients with AR disease. In a 
Th2 skewed environment IL-17 can promote eosinophils 
survival and degranulation via GM-CSF [17]. In a Th1/
Th17 skewed environment, IL-17 has been shown to pro-
mote autoimmunity and bone resorption but our findings 
demonstrate that in atopy IL-17 and ECP protein may 
augment nasal inflammation in AR patients [15, 17].
We also found a significant correlation between serum 
ECP and IgE levels in the AR patients. To our knowledge 
no previous studies have proven a correlation between 
ECP and IgE in AR disease. An explanation for this find-
ing may be that the eosinophil degranulates and releases 
mediators such as ECP after contact with IgE through 
surface receptors in allergic diseases. In accordance with 
the findings of Voice et al. [35] there was however no sig-
nificant correlation between serum IL-17 and IL-33 levels 
in the AR group.
We found a significant correlation between symptom 
scores and eosinophil count. Apar et  al. also showed a 
significant correlation between eosinophil count and 
the symptom severity score for AR [36] and Chen et al. 
observed a correlation of eosinophil count with the 
symptom severity score of perennial allergic rhinitis 
(PAR) [37]. In our study a high proportion, 80% of the 
patients had PAR. We did also find a significant cor-
relation between IgE levels and symptom scores. AR 
symptoms, either sneezing-rhinorrhea or nasal obstruc-
tion, might therefore occur due to the release of allergic 
mediators, such as histamine when allergens cross-links 
IgE bound to the surface of MCs in AR patients [8]. 
Moreover, the study by Chen et  al. shows that levels of 
IgE have been correlated with symptom severity score in 
PAR patients [37].
No statistically significant correlation was found 
between ECP, IL-17, IL-33 levels and symptom scores. 
This result is in agreement with one previous study [38]. 
In contrast to our results Chen et al. found the symptom 
severity score was correlated with serum ECP levels in 
PAR patients [37]. Our results are also in disagreement 
with those reported by Ciprandi and Gluck where a sig-
nificant correlation between symptom severity score and 
IL-17 and also IL-33 was found [31, 39, 40].
Conclusion
In conclusion, patients with AR have higher serum lev-
els of ECP, IL-17, and IL-33 than healthy controls. This 
indicates that these markers could be used to in order to 
diagnose AR patients and also that inhibitory molecules 
blocking IL-17 and IL-33 might be considered as future 
therapeutic targets.
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